SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1707Really curious on this readout as well as Eylea + PDGFR mAb or Eylead + Ang2 mAbFelix B-1/29/2015
1706NVS will present data from two phase-2 trials of RTH258 vs Lucentis/Eylea at TheDewDiligence_on_SI-1/28/2015
1705Competing bispecific , CD19-CD3; finance.yahoo.comMiljenko Zuanic-1/27/2015
1704It is good to see that they are going after Aflibercept. The turning point will Miljenko Zuanic-1/27/2015
1703NVS starts phase-3 trial of RTH258 vs Eylea: siliconinvestor.comDewDiligence_on_SI-1/27/2015
1702Ops, technology is leaking to outsiders! en.sanofi.com Where is REGN allocatingMiljenko Zuanic-1/15/2015
1701L.Sc. show some weakness against X. Scripts. Hope Sanofi is not pressed by at &Miljenko Zuanic-1/14/2015
1700JPMorgan presentation: investor.regeneron.comBiotech Jim-1/14/2015
1699PCSK9 Filing? REGN has mentioned numerous times it would file by end of 2014 Q4Felix B-1/6/2015
1698It is strange as you said that she would buy open market rather than exercising Felix B-12/1/2014
1697Jim, we all know that you have high confidence in REGN. My point was why she didMiljenko Zuanic-11/29/2014
1696We'd like to have a logo on this board as part of our site modernization aSI Ron (Crazy Music Man)-11/28/2014
1695I stopped selling about 18 months ago, from the shares I bought in 2004. I thenBiotech Jim-11/28/2014
1694PS: In last 24 months she is the ONLY insider who openly bought REGN shares. StrMiljenko Zuanic-11/27/2014
1693Christine A. Poon is betting $164K on REGN, while all other insiders (except purMiljenko Zuanic-11/27/2014
1692IMPROVE-IT: OT-analysis confirmed benefit of the lower LDL-C (~17 mg/dL differenMiljenko Zuanic-11/19/2014
1691Yes, difference after 4 years appears to be constant. If in PP analysis deferenMiljenko Zuanic-11/17/2014
1690Curiously, all of the IMPROVE-IT ITT benefit was seen in the period 1-4 years frDewDiligence_on_SI-11/17/2014
1689Very modest benefit (relative ~6% reduction over 7 years on drug) from further Miljenko Zuanic-11/17/2014
1688IMPROVE-IT ITT results: siliconinvestor.comDewDiligence_on_SI-11/17/2014
1687Monday, November 17, 2014 8:30 am EST mercknewsroom.com Merck Announces that IBiotech Jim-11/17/2014
1686NPC1L1 inactivating mutations: nejm.orgMiljenko Zuanic-11/12/2014
1685I understand what you are saying. I am bit expanding thinking, what may influencMiljenko Zuanic-11/10/2014
1684For influencing future policy vis-à-vis the LDL biomarker, there’s no reasoDewDiligence_on_SI-11/10/2014
1683Well, trial did experience protocol changes during the course, but standard (LDLMiljenko Zuanic-11/10/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News